Opioid Ranking by μ-Opioid Receptor Binding Affinity
Buprenorphine has the highest binding affinity to the μ-opioid receptor among clinically used opioids, followed by fentanyl, with morphine serving as the reference standard. 1
Binding Affinity Hierarchy (Strongest to Weakest)
Based on the guideline evidence and relative effectiveness data, the ranking from strongest to weakest μ-opioid receptor binding is:
Highest Binding Affinity:
Buprenorphine - Described as having "high binding affinity for the μ-opioid receptor" with the ability to prevent other full agonist opioids from accessing the receptor due to this strong binding 1. The evidence explicitly states that buprenorphine's high affinity "diminishes the ability of other more potent full agonist opioids to dislodge it from the receptor" 1. This is quantified with relative effectiveness of 75-100 times morphine depending on route 2.
Fentanyl - Relative effectiveness of 7.5 times morphine (IV) and 4 times morphine (transdermal) 2, indicating very high receptor affinity.
Hydromorphone - Relative effectiveness of 5-7.5 times morphine 2, 3, 4.
Oxymorphone - Relative effectiveness of 3 times morphine 3.
Methadone - Relative effectiveness of 4-12 times morphine (variable based on dose) 2, 3, 2.
Oxycodone - Relative effectiveness of 1.5-2 times morphine 2, 3, 2, 4.
Hydrocodone - Relative effectiveness of 1.0 (equivalent to morphine) 3.
Lowest Binding Affinity:
Tramadol - Relative effectiveness of 0.1-0.2 times morphine 2, 3, 2, 4. Research confirms tramadol itself has weak affinity (Ki=2.4 μM), with its metabolite (+)-M1 being the active component 5.
Codeine - Relative effectiveness of 0.15-0.17 times morphine 2, 3, 2, 4. Codeine is a prodrug requiring CYP2D6 metabolism to morphine for analgesic effect 6.
Critical Clinical Implications
Buprenorphine's exceptionally high binding affinity creates a unique clinical challenge: When patients on buprenorphine require additional pain control, usual doses of other opioids are ineffective because buprenorphine blocks receptor access 1. The guidelines specifically recommend that "if usual doses of an additional opioid are ineffective for improving chronic pain, we recommend a closely monitored trial of higher doses of an additional opioid" due to this receptor blockade 1.
Route of administration significantly affects binding characteristics: Parenteral routes show 3-fold higher relative effectiveness than oral for morphine and other opioids due to bypassing first-pass metabolism 2, 4.
Important caveats: Binding affinity does not directly correlate with clinical analgesic potency—buprenorphine is a partial agonist despite highest binding affinity, creating a ceiling effect for analgesia 1, 7. Conversely, fentanyl is a full agonist with both high binding affinity and high intrinsic activity, making it extremely potent clinically.